<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FLUVOXAMINE</span><br/>(flu-vox'a-meen)<br/><span class="topboxtradename">Luvox<br/></span><b>Classifications:</b> <span class="classification">central nervous system (cns) agent</span>; <span class="classification">psychotherapeutic agent</span>; <span class="classification">selective serotonin reuptake inhibitor (ssri)</span><br/><b>Prototype: </b>Fluoxetine<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg, 50 mg, 100 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Antidepressant with potent, selective, inhibitory activity on neuronal (5-HT) serotonin reuptake (SSRI); structurally unrelated
         to TCAs. Compared with TCAs, shows fewer anticholinergenic effects and no severe cardiovascular effects.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective as an antidepressant and for control of obsessive-compulsive disorders.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of depression and obsessive-compulsive disorders.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Chronic tension-type headaches, panic attacks.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to fluvoxamine or fluoxetine; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category B), lactation, liver disease, renal impairment, abrupt discontinuation; cardiac disease, dehydration,
         hyponatremia, older adults, ECT, seizure disorders, seizures, suicidal ideation, tobacco smoking.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Depression, Obsessive-Compulsive Disorder</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 50 mg q.d., may increase slowly up to 300 mg/d given q.h.s. or divided b.i.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>811 y,</i> Start with 25 mg q.h.s., may increase by 25 mg q47d (max: 200 mg/d in divided doses)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give starting doses at bedtime to improve tolerance to nausea and vomiting; both are common early in therapy.</li>
<li>Store at room temperature, 15°30° C (59°86° F), away from moisture and light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Somnolence, headache, agitation, insomnia, dizziness,</span> seizures. <span class="typehead">CV:</span> Orthostatic hypotension, slight bradycardia. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, dry mouth, constipation, anorexia</span>. <span class="typehead"> Urogenital:</span> Sexual dysfunction. <span class="typehead">Skin:</span>
<span class="speceff-life">Stevens-Johnson syndrome</span>, <span class="speceff-life">toxic epidermal necrolysis</span> (rare). 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>
<span class="alt">Gamma-glutamyl transferase</span> increased by more than 3-fold following 3 wk of therapy.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span> Fluvoxamine has been shown to significantly increase plasma levels of <b>amitriptyline,</b>
<b>clomipramine,</b> and other <span class="classification">tricyclic antidepressants</span> to mildly increase levels of their metabolites. May antagonize the blood pressure-lowering effects of <b>atenolol</b> and other <span class="classification">beta blockers</span>. May increase levels and toxicity of <b>carbamazepine,</b>
<b>mexiletine.</b> May increase <b>lithium</b> levels causing neurotoxicity, <b>serotonin</b> syndrome, somnolence, and mania. One report of increased <b>theophylline</b> levels with toxicity. Increases prothrombin time in patients on <b>warfarin;</b> increased ergotamine toxicity with <b>dihydroergotamine,</b>
<b>ergotamine.</b> Use with <span class="classification">cyp 1a2 inhibitors</span> <b>(thioridazine,</b>
<b>pimozide,</b>
<b>alosetron,</b>
<b>tizanidine)</b> increases fluvoxamine levels and toxicity.  <span class="typehead">Herbal:</span>
<b>Melatonin</b> may increase and prolong drowsiness; <b>St. John's wort</b> may cause <b>serotonin</b> syndrome. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Almost completely absorbed from GI tract. <span class="typehead">Onset:</span> 47 d. <span class="typehead">Distribution:</span> Approximately 77% bound to plasma proteins; excreted in human breast milk but in an amount that poses little risk to the
      nursing infant. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Completely excreted in urine. <span class="typehead">Half-Life:</span> 1624 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for significant nausea and vomiting, especially during initial therapy.</li>
<li>Monitor for worsening of depression or emergence of suicidal ideations.</li>
<li>Assess safety; drowsiness and dizziness are common adverse effects.</li>
<li>Monitor PT and INR carefully with concurrent warfarin therapy; adjust warfarin as needed.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>
            							Note: Nausea and vomiting are common in early therapy. Notify physician if these adverse effects last more than a few days.
            						
         </li>
<li>Exercise caution with hazardous activity until response to the drug is known.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>